NEW YORK (GenomeWeb News) – RNAi research services company Cenix BioScience said today it has signed an agreement to help CellCentric validate oncology drug candidates.
 
Dresden, Germany-based Cenix said it will combine high-throughput applications of RNAi-based gene silencing with high-content phenotypic analyses in cultured human cells to provide in vitro validation of several of CellCentric’s drug candidates.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.